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Expression Profiling of Metalloproteinases and
Tissue Inhibitors of Metalloproteinases in Normal and
Degenerate Human Achilles Tendon
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Dylan R. Edwards,2 Michelle M. Bradley,3 Brian L. Hazleman,1 and Graham P. Riley1
Objective. To profile the messenger RNA (mRNA)
expression for the 23 known genes of matrix metallo-
proteinases (MMPs), 19 genes of ADAMTS, 4 genes of
tissue inhibitors of metalloproteinases (TIMPs), and
ADAM genes 8, 10, 12, and 17 in normal, painful, and
ruptured Achilles tendons.
Methods. Tendon samples were obtained from
cadavers or from patients undergoing surgical proce-
dures to treat chronic painful tendinopathy or ruptured
tendon. Total RNA was extracted and mRNA expression
was analyzed by quantitative real-time reverse
transcription–polymerase chain reaction, normalized to
18S ribosomal RNA.
Results. In comparing expression of all genes, the
normal, painful, and ruptured Achilles tendon groups
each had a distinct mRNA expression signature. Three
mRNA were not detected and 14 showed no significant
difference in expression levels between the groups.
Statistically significant (P < 0.05) differences in mRNA
expression, when adjusted for age, included lower levels
of MMPs 3 and 10 and TIMP-3 and higher levels of
ADAM-12 and MMP-23 in painful compared with nor-
mal tendons, and lower levels of MMPs 3 and 7 and
TIMPs 2, 3, and 4 and higher levels of ADAMs 8 and 12,
MMPs 1, 9, 19, and 25, and TIMP-1 in ruptured
compared with normal tendons.
Conclusion. The distinct mRNA profile of each
tendon group suggests differences in extracellular pro-
teolytic activity, which would affect the production and
remodeling of the tendon extracellular matrix. Some
proteolytic activities are implicated in the maintenance
of normal tendon, while chronically painful tendons and
ruptured tendons are shown to be distinct groups. These
data will provide a foundation for further study of the
role and activity of many of these enzymes that underlie
the pathologic processes in the tendon.
Pathologic conditions in the tendon are common,
representing a significant proportion of referrals for
soft-tissue symptoms among patients in rheumatology
clinics. The most common finding during surgery for
chronic pain of the Achilles tendon is intratendinous
degeneration or tendinosis (1). Histopathologic exami-
nation of normal Achilles tendon tissue identified dense,
straight or slightly wavy, parallel-packed collagen fibers
with rows of cells, vessels, and nerves located between
the fiber bundles, whereas degenerate, painful tendon
samples contained increased amounts of noncollagenous
matrix, alterations in the structure and arrangement of
collagen fibers, and focal variations in cellularity and
vascularization (2). Many patients with ruptured Achil-
les tendons have no symptoms prior to rupture; never-
theless, degeneration is thought to precede the tendon
rupture (1). A study of spontaneously ruptured tendons
identified hypoxia and loss of fibrillar collagen structure
as characteristic pathologic features of the tissue (3).
The biomechanical properties of the tendon
are primarily a feature of the extracellular matrix
(ECM), which is in a state of dynamic equilibrium
between synthesis and degradation (4). Degradation of
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the ECM is principally mediated by proteinases, whose
activities may be regulated at the transcriptional or the
translational levels, or posttranslationally by processing
or interaction with inhibitors. The metalloproteinase
clan of enzymes has been implicated in a wide range of
extracellular proteolytic events, and its members include
the matrix metalloproteinase (MMP), ADAM, and
ADAMTS groups.
Members of the MMP family can degrade the
majority of ECM components (5) and have been impli-
cated in ECM remodeling of the tendon (6,7). The
family consists of 23 human gene products, including 5
with activity against fibrillar collagen (MMPs 1, 2, 8, 13,
and 14). The ADAM family consists of more than 30
members, with both proteolytic and signaling activities
(8,9). ADAM family members may participate in inflam-
matory processes through the proteolytic release of
inflammatory mediators from the cell membrane, such
as the cleavage by ADAM-17 of membrane-bound tu-
mor necrosis factor  (TNF) to the more proinflam-
matory soluble form (10). The ADAMTS family consists
of 19 human gene products, which include N-terminal
procollagen propeptidases (ADAMTS-2, -3, and -14)
and aggrecanases (ADAMTS-1, -4, -5, -8, -9, and -15)
that appear to participate in early degradative events of
arthritic cartilage, and are implicated in tendon-matrix
turnover (11–13). Aggrecanases cleave aggrecan at char-
acteristic sites located C-terminal to a glutamate residue
(14), but some members also cleave related proteogly-
cans such as versican and brevican at equivalent sites
(15–17). ADAMTS-4 has also been shown to cleave
other, nonproteoglycan ECM components such as car-
tilage oligomeric matrix protein (18), fibromodulin, and
decorin (19).
The tissue inhibitors of metalloproteinases
(TIMPs) family contains 4 human gene products that are
physiologic inhibitors of metalloproteinases. Generally,
all TIMP members inhibit MMP members to varying
degrees, although functional differences have been iden-
tified (20). In comparison, TIMP inhibition of ADAM
and ADAMTS members appears to be more restricted,
with TIMP-3 typically the most potent inhibitor of
members of these families (21–23).
The local balance of metalloproteinases and
TIMP proteins is likely to be of importance in the
correct maintenance of tendon ECM, and alterations to
the synthetic–degradative equilibrium may underlie the
degenerative changes observed during pathologic devel-
opment in the tendon. We have previously identified a
down-regulation of MMP-3 messenger RNA (mRNA)
expression in the pathologic process (24), but a system-
atic analysis of MMP, ADAMTS, and TIMP members
has not been undertaken. Such an approach is necessary
to identify those genes expressed in the tendon and
those that are altered in pathologic processes.
The aim of this study was to assess the mRNA
expression levels for the 23 known MMP genes, 19
known ADAMTS genes, 4 known TIMP genes, and
ADAM genes 8, 10, 12, and 17 in normal healthy
samples, chronically painful samples, and ruptured sam-
ples of human Achilles tendon tissue, in order to com-
pare the groups and identify gene targets for further
investigation.
PATIENTS AND METHODS
Tendon specimens. The tendon specimens analyzed
were as follows: 1) macroscopically normal specimens from
cadaver material, obtained within 48 hours of death; 2) tissue
from individuals with painful tendinopathy for more than 6
months, obtained from the site of the lesion (in the tendon
midsubstance) during surgery and having an abnormal histo-
logic appearance; 3) tissue from individuals undergoing repair
of ruptured tendon mostly within 48 hours of occurrence of the
rupture, trimmed from the site of the rupture. All procedures
had appropriate local ethics committee approval, and in-
formed consent was obtained from all patients. Samples from
a total of 32 individuals, all of whom were men, were included
in the study, and comprised 11 normal, 9 painful, and 12
ruptured Achilles tendons. The age distribution of individuals
within each tendon classification at the time of tissue collection
was as follows: normal tendon group mean age 49 years, range
20–76 years, painful tendinopathy group mean age 45 years,
range 33–59 years, ruptured tendon group mean age 42 years,
range 25–53 years. Specimens were transported to the labora-
tory in ice-cold balanced salt solution, and dissected pieces of
midtendon (between 10 mg and 70 mg wet weight) were frozen
at 70°C.
Histochemical analysis. Tissue samples were frozen
and sectioned for histochemical analysis. Sections were pro-
cessed using standard procedures, including hematoxylin and
eosin, toluidine blue, and Alcian blue staining.
RNA isolation from tendon tissue samples. Total RNA
was isolated from frozen tissue samples by a modified Tri-Spin
protocol as described previously (24) and resuspended in 100
l water. The concentration of RNA was estimated using a
NanoDrop spectrophotometer (courtesy of Prof. D. E. Neal’s
group at the Hutchison/MRC Research Centre, Cambridge,
UK). The majority of samples yielded between 20 ng and 70 ng
RNA/mg wet weight, consistent with the low cellularity of
tendon, and the ratio of absorbance at 260 nm to 280 nm was
1.68  0.04 (mean  SEM). The RNA was diluted to 1 ng/l
and stored at 70°C as aliquots, which were thawed once only.
Quantitative real-time polymerase chain reaction
(PCR). Complementary DNA (cDNA) was prepared using
SuperScript II (Invitrogen, Paisley, UK) and primed using
random hexamers (Amersham Biosciences, Chalfont St.Giles,
UK) according to the manufacturer’s instructions. Two hun-
dred fifty ng RNA was used for cDNA preparation, with the
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exception of 3 samples for which lesser amounts of RNA were
available and therefore only 125 ng RNA was used. The cDNA
was stored at 20°C until required for quantitative real-time
PCR.
For PCRs, specific primers and fluorogenic probes for
all 23 human MMP genes, all 4 human TIMP genes, all 19
human ADAMTS genes, and human ADAM genes 8, 10, 12,
and 17 were designed using Primer Express 1.0 software (PE
Applied Biosystems, Warrington, UK). The primer and probe
sequences for the MMP and TIMP genes have been described
previously by Nuttall et al (25), and for the ADAMTS genes by
Porter et al (26). The primer and probe sequences for ADAMs
8, 10, 12, and 17 were as follows: ADAM-8, forward primer
AAGCAGCCGTGCGTCATC, reverse primer AACCTGTC-
CTGACTATTCCAAATCTC, probe AATCACGTGGA-
CAAGCTATATCAGAAACTCAACTTCC; ADAM-10, for-
ward primer AGCGGCCCCGAGAGAGT, reverse primer
AGGAAGAACCAAGGCAAAAGC, probe ATCAAATGG-
GACACATGAGACGCTAACTGC; ADAM-12, forward
primer AGCTATGTCTTAGAACCAATGAAAAGTG, re-
verse primer CCCCGGACGCTTTTCAG, probe ACCAACA-
GATACAAACTCTTCCCAGCGAAGA; ADAM-17, for-
ward primer GAAGTGCCAGGAGGCGATTA, reverse
primer CGGGCACTCACTGCTATTACC, probe TGCTA-
CTTGCAAAGGCGTGTCCTACTGC.
To control against amplification of genomic DNA,
primers were designed, where possible, so that amplicons
crossed intron–exon boundaries. The 18S ribosomal RNA
(rRNA) gene was used as an endogenous control to normalize
for differences in the amount of total RNA in each sample, and
18S rRNA primers and probe were purchased from PE
Applied Biosystems. PCRs were performed using the ABI
Prism 7700 Sequence Detection System (PE Applied Biosys-
tems), according to the manufacturer’s protocol. Each reaction
was performed in 25 l and contained the equivalent of either
1 ng of reverse-transcribed RNA for 18S analysis or 4 or 5 ng
for analysis of other genes (half of these amounts were used for
the 3 samples containing low RNA levels), 50% TaqMan 2
PCR Master Mix (PE Applied Biosystems), 100 nM each of the
forward and reverse primer, and 200 nM of probe. Conditions
for the PCR were 2 minutes at 50°C, 10 minutes at 95°C, and
then 40 cycles, each consisting of 15 seconds at 95°C and 1
minute at 60°C.
The ABI Prism 7700 measured the cycle–cycle changes
in fluorescence in each sample and generated a kinetic profile
of DNA amplification over the 40-cycle PCR. The cycle
number (termed the cycle threshold [Ct]) at which amplifica-
tion entered the exponential phase was determined and this
number was used as an indicator of the amount of target RNA
in each tissue; that is, a lower Ct indicated a higher quantity of
starting RNA. Gene expression levels relative to that of 18S
rRNA were calculated from the Ct values (calculated as 18S
rRNA Ct  gene Ct), using an assumption of maximal
amplification efficiency in each reaction with the formula 2Ct.
This assumption may overestimate the magnitude of change of
a single target mRNA between clinical groups, but will not
affect the significance of such comparisons. In contrast, the
magnitude of expression of distinct target mRNA may be
overestimated to differing degrees, so that comparison of
mRNA levels of different genes should only be regarded as
approximate.
Statistical analysis. SPSS statistical software was used
for all statistical analyses (SPSS, Chicago, IL). All analyses
were performed on the relative gene expression levels, which
were simple transformations of the Ct value. Samples with an
undetectable gene expression level (i.e., a gene Ct value of
40) were given an arbitrary expression level of zero. Analyses
of the effect of age and tendon group on the observed relative
gene expression levels were performed by analysis of covari-
ance (ANCOVA) where appropriate, or by a nonparametric
equivalent (27) when the data did not fit the assumptions of
this test. Three linear contrasts were included in the ANCOVA
model, painful versus normal tendon, ruptured versus normal
tendon, and ruptured versus painful tendon, the results of
which were adjusted for multiple testing using a Bonferroni
correction. A P value of less than 0.05 was regarded as
statistically significant.
RESULTS
Characterization of tendon tissue samples. A
histologic analysis was conducted to characterize the 3
groups of tendon samples. Eight of the 11 cadaver
tendons showed a mostly normal histologic appearance,
although there were some variations in cell shape and
density. The sections consisted of mostly longitudinally
oriented fibrous matrix, and the majority of cells were
long, thin, and aligned with the collagen fibers, essen-
tially as described elsewhere (1–3,28). Some cell and
matrix abnormalities were observed in 3 cadaver tendon
specimens (27%), such as an increased proportion of
rounded cells, some loss of matrix organization, loss of
crimp, increased amounts of interfascicular loose con-
nective tissue, and increased staining for matrix glycos-
aminoglycans. These observations are consistent with
those of a previous study, which described at least some
features of degenerative change in 34% of cadaver
tendons (3).
Seven of the 9 painful tendons showed histologic
features characteristic of painful tendinopathy, with loss
of the normal fibrillar structure, loss of cell orientation,
an increase in the number of fibroblasts, an increased
proportion of ovoid or rounded cells (sometimes clus-
tered or in small rows), and increased matrix glycosami-
noglycan staining. Similar changes were reported in a
large study of painful Achilles tendinopathy (1). Most
specimens showed some blood vessel infiltration into the
fibrillar matrix, a feature that has been associated with
the onset of clinical symptoms in the tendon (29). Two
specimens of tendon with painful tendinopathy did not
show increased cellularity but did exhibit other abnor-
malities, as evidenced by hypocellular regions (com-
pared with normal tendon), rounded cells, increased
matrix glycosaminoglycan, and a few scattered blood
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vessels penetrating the fibrils. Only 1 specimen showed
small clusters of infiltrating lymphocytes and plasma
cells.
Nine of the 12 ruptured tendons showed a loss of
the organized fibrillar structure and were generally less
cellular compared with normal tendon (most specimens
contained acellular regions). The cells and nuclei were
frequently rounded and shrunken, and there was no
evidence of blood vessel infiltration. These changes were
similar to those reported in a large study of spontane-
ously ruptured tendons (3). Three specimens showed at
least some regions of increased cellularity and some
blood vessel infiltration between the fibers, similar to
that described in painful tendinopathy specimens. Four
specimens showed small clusters of infiltrating inflam-
matory cells.
The quality of the RNA in normal and pathologic
samples was investigated by electrophoresis, using 100–
200 ng each of 3 RNA samples from each tendon group.
Samples chosen for this analysis were those from which
the highest amounts of total RNA were extracted. In all
cases, clear sharp bands of 28S and 18S rRNA were
observed, with the 28S band brighter than the 18S band.
No diffuse staining was observed at lower molecular
mass, suggesting that there was relatively little degener-
ation of this RNA.
Analysis of gene expression. The mRNA expres-
sion levels for all of the known human MMP, ADAMTS,
and TIMP genes and ADAM genes 8, 10, 12, and 17 in
normal, chronically painful, and ruptured Achilles ten-
dons were determined by quantitative real-time PCR. Of
the 50 genes investigated, only mRNA for MMPs 20 and
26 and ADAM-10 were not detected in any of the
specimens, although the expression of mRNA for
ADAMTS-20 was also below the level of detection in
over half of the samples in all 3 groups. The relative
mRNA levels for each gene in the normal, painful, and
ruptured tendon groups are illustrated in Figure 1.
Overall, the most highly expressed mRNA were MMPs 2
Figure 1. Expression of mRNA, relative to 18S ribosomal RNA, for
matrix metalloproteinase (MMP), ADAMTS, ADAM, and tissue
inhibitor of metalloproteinases (TIMP) genes isolated from samples of
normal (open bars), painful (shaded bars), and ruptured (diagonally
hatched bars) human tendon. Lines within the boxes represent the
median, the boxes represent the 25th and 75th percentiles, and the
lines outside the boxes correspond to the minimum and maximum
values. ND  not detectable.
Figure 2. Correlation between age and the relative expression level of
mRNA (in arbitrary units) encoded by ADAMTS-1, ADAMTS-10,
MMP-15, MMP-25, and TIMP-3 genes in normal, painful, and rup-
tured Achilles tendon samples. See Figure 1 for definitions.
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and 3 and TIMPs 1, 2, and 3, and those with the lowest
detectable expression (up to 106-fold lower) were
MMP-8 and ADAMTS-7, -8, -18, and -20.
The mRNA expression levels for all genes were
tested for an association with age and tendon group,
using ANCOVA. This analysis effectively fits parallel
regression lines of expression level against age for each
tendon group. Differences between the lines are then
attributable to tendon group (in effect, each group is
compared at a single age value) and these differences
are tested for significance. The ANCOVA method also
tests the significance of any effect of age, which is
adjusted for tendon group.
The mRNA expression levels for 5 of the 47
detected genes (ADAMTS-1 and -10, MMPs 15 and 25,
and TIMP-3) had a significant association with age (P 
0.05 by ANCOVA). In all cases, the mRNA expression
levels tended to decrease with increasing age (Figure 2).
Among these 5 genes, significant differences in the
mRNA levels between the tendon groups were also
detectable for ADAMTS-10, MMP-25, and TIMP-3.
With the use of ANCOVA, 33 genes were iden-
tified whose mRNA expression levels differed signifi-
cantly between tendon groups. These genes were then
further analyzed using pairwise comparisons of the 3
tendon groups. The results of these analyses are sum-
marized in Table 1. Fourteen genes (ADAM-17,
ADAMTS-1, -6, -8, -9, -12, -15, -16, -18, -19, and -20 and
MMPs 2, 13, and 15) showed no significant difference in
mRNA expression between the 3 groups. The mRNA
expression levels for 12 genes were significantly different
in chronically painful tendons as compared with normal
samples (6 with lower levels and 6 with higher levels),
while the levels of mRNA for 20 genes were different in
ruptured tendons as compared with normal samples (9
with lower levels and 11 with higher levels). In compar-
ing ruptured tendons with chronically painful tendons,
the expression levels of mRNA for 23 genes were
different (13 with lower levels and 10 with higher levels).
The principal differences in mRNA expression
were a lower level of MMP-3 and TIMP-3 and higher
level of ADAM-12 and MMP-11 mRNA in both the
painful and ruptured tendon groups compared with the
normal samples; a lower level of ADAMTS-5 and MMPs
10, 12, and 27 and higher level of ADAMTS-2 and -3
and MMPs 16 and 23 mRNA in the painful tendon
group compared with the normal tendon group; a lower
level of ADAMTS-7, MMPs 7, 24, and 28, and TIMPs 2
and 4 and a higher level of ADAM-8, ADAMTS-4,
MMPs 1, 9, 14, 19, and 25, and TIMP-1 mRNA in the
ruptured tendon group compared with the normal ten-
don group; and a lower level of ADAMTS-2, -3, and -17,
MMPs 7, 16, 23, 24, and 28, and TIMPs 2, 3, and 4 and
a higher level of ADAMs 8 and 12, ADAMTS-4, MMPs
1, 8, 10, 12, 19, and 25, and TIMP-1 mRNA in the
ruptured tendon group compared with the painful ten-
don group (Table 1).
DISCUSSION
This study is the first to investigate the mRNA
expression levels for genes from the MMP, ADAMTS,
and TIMP families (and selected ADAM family mem-
bers) in Achilles tendon tissue from patients with chron-
ically painful tendinopathy or tendon rupture, as com-
pared with normal Achilles tendon. The pattern of
mRNA expression across the complete gene set was
distinct for each tendon group, suggesting that each
group represented a distinct tissue state. The present
study was limited to the investigation of mRNA, and it is
therefore unknown whether any corresponding variation
occurred in absolute protein levels or de novo synthesis.
However, it is reasonable to speculate that the differ-
ences in the mRNA levels of metalloproteinases and
their inhibitors in tendon disease states would result in
distinct extracellular proteolytic activities, potentially
affecting the structure and function of the tendon ECM.
Tendon “overuse” has been proposed as a de-
structive mechanism that precedes overt pathologic de-
velopment, implying that repeated strains below the
injury threshold induce changes in the tendon-matrix
composition and organization (28,30). Since metallopro-
teinase expression in tendon cells is known to be mod-
ulated by mechanical loading (31–34), it is possible,
given the absence of inflammation in most specimens,
that at least some of the changes in gene expression
described herein are induced by an altered mechanical
environment. Remodeling of the tendon matrix may be
induced by increased levels of strain and shear or
compressive forces acting on the tissue. Alternatively,
there may be a catabolic response to the local loss of
strain as a result of microscopic fiber damage. In support
of this, it has been demonstrated that stress-shielded and
immobilized ligaments and tendons rapidly lose their
mechanical properties (35,36), an effect requiring viable
cells and mediated via the activity of metalloproteinases
such as collagenase (37,38). Although there was no
known bias in the physical activity level of the popula-
tions from which samples of each type of tendon were
obtained, it is possible that differences in loading be-
tween (and within) the sample groups might account for
some of the observed variation. The analysis of such
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variables was beyond the scope of the present study but
should be considered when interpreting these results.
It is evident from this study that normal tendon
tissue expresses a spectrum of metalloproteinases and
TIMP mRNA, which suggests that regulated metallo-
proteinase activities are important in the homeostasis of
this tissue. The musculoskeletal syndrome observed fol-
lowing administration of broad-spectrum metallopro-
Table 1. Differences in gene expression levels, corrected to 18S ribosomal RNA, between normal and pathologic Achilles tendon groups*
Gene
Association of tendon
group with gene
expression level, P
Fold difference in gene expression (P)
Painful compared
with normal tendon
Ruptured compared
with normal tendon
Ruptured compared
with painful tendon
MMP-1 0.0001 1,021 (0.0001) 734 (0.0004)
MMP-2 0.07
MMP-3 0.0001 41 (0.0002) 18 (0.002)
MMP-7 0.0001 32 (0.0001) 27 (0.0001)
MMP-8 0.006 36 (0.005)
MMP-9 0.003 40 (0.003)
MMP-10 0.0001 88 (0.0001) 35 (0.0004)
MMP-11 0.0003 5 (0.003) 6 (0.0004)
MMP-12 0.0005 19 (0.001) 23 (0.002)
MMP-13 0.23
MMP-14 0.008 3 (0.007)
MMP-15 0.06
MMP-16 0.0006 3 (0.002) 3 (0.002)
MMP-17 0.04 2 (0.05)
MMP-19 0.0001 27 (0.0001) 35 (0.0001)
MMP-21 0.01 3 (0.02)
MMP-23 0.0005 6 (0.001) 5 (0.002)
MMP-24 0.0004 6 (0.001) 5 (0.003)
MMP-25 0.0001 21 (0.0001) 27 (0.0001)
MMP-27 0.008 10 (0.007)
MMP-28 0.0001 7 (0.0001) 10 (0.0001)
ADAMTS-1 0.60
ADAMTS-2 0.01 3 (0.03) 3 (0.03)
ADAMTS-3 0.009 4 (0.02) 4 (0.02)
ADAMTS-4 0.0009 8 (0.001) 5 (0.01)
ADAMTS-5 0.003 4 (0.002)
ADAMTS-6 0.07
ADAMTS-7 0.004 7 (0.002)
ADAMTS-8 0.54
ADAMTS-9 0.62
ADAMTS-10 0.04 2 (0.04)
ADAMTS-12 0.12
ADAMTS-13 0.02 2 (0.02)
ADAMTS-14 0.04
ADAMTS-15 0.58
ADAMTS-16 0.48
ADAMTS-17 0.0005 3 (0.0004)
ADAMTS-18 0.59
ADAMTS-19 0.68
ADAMTS-20 0.09
TIMP-1 0.0001 8 (0.0001) 5 (0.0001)
TIMP-2 0.0001 16 (0.0001) 11 (0.0001)
TIMP-3 0.0001 2 (0.007) 7 (0.0001) 4 (0.0001)
TIMP-4 0.0001 9 (0.0001) 10 (0.0001)
ADAM-8 0.0001 19 (0.002) 20 (0.0001)
ADAM-12 0.0001 13 (0.0001) 107 (0.0001) 8 (0.0001)
ADAM-17 0.82
* The probabilities of expression levels being independent of group were calculated using analysis of covariance (ANCOVA) where appropriate, or
a nonparametric equivalent (for matrix metalloproteinases [MMPs] 7, 8, 9, 10, 12, 13, 17, 21, 23, and 25, ADAMTS-12, ADAMTS-14, ADAMTS-16,
ADAMTS-19, and ADAMTS-20, and ADAM-8), including age as a covariate. Where a significant association between tendon group and mRNA
expression level was identified by ANCOVA, pairwise group comparisons were performed post hoc and adjusted for multiple comparisons using a
Bonferroni correction. Only significantly different pairwise comparisons are given. Fold differences were derived from the age-corrected mean
expression level in each group, as estimated from the ANCOVA model. TIMP-1  tissue inhibitor of metalloproteinases 1.
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teinase inhibitors (39) might therefore be the result of
the disruption of homeostatic turnover. The most highly
expressed mRNA were MMPs 2 and 3, which were
present at levels more than 10-fold higher than any other
metalloproteinase, and TIMP-3, which was present at a
similar level. Other highly expressed mRNA included
the TNF-cleaving enzyme, ADAM-17, the aggrecanase
proteinases ADAMTS-1, -5, and -9, the procollagen
N-propeptidase ADAMTS-2, the membrane-type met-
alloproteinases MMPs 14 and 15, and the metallopro-
teinase inhibitors TIMPs 1, 2, and 4.
Analysis of the data identified 5 genes whose
mRNA levels correlated with age. In all cases, the
mRNA levels tended to decrease with increasing age,
the largest decreases being observed with the
membrane-type metalloproteinases MMP-15 and MMP-
25. The cause of this age-associated change in mRNA
expression is unknown. Levels of mRNA may alter as a
direct consequence of aging, but changes could also be
due to other age-associated effects, such as reduced
loading as a result of changes in physical activity.
Genes with a different mRNA level in chronically
painful tendon compared with normal tissue are sum-
marized in Table 2. Differences between the painful and
normal tendon samples included a lower level of the
aggrecanase ADAMTS-5, MMPs 3, 10, 12, and 27, and
TIMP-3 mRNA and a higher mRNA level of ADAM-12,
the procollagen N-propeptidases ADAMTS-2 and -3,
and MMPs 11, 16, and 23.
The levels of MMP-3 mRNA in the painful
tendon group were 1–2 orders of magnitude lower than
those in the normal tendon group, an observation that is
consistent with a previous analysis by us and which has
also been observed at the protein level (24). MMP-3 has
been proposed as a central regulator of MMP activation
(40,41) and its down-regulation may serve to limit MMP
activation within the tissue. The level of MMP-10
mRNA, which is phylogenetically similar to MMP-3
(42), was also lower in the painful tendon samples, by a
similar magnitude.
The levels of ADAM-12 mRNA were an order of
magnitude higher in painful tendon samples than in the
normal tendons. ADAM-12 has been demonstrated to
cleave insulin-like growth factor binding proteins 3 and
5, pro–heparin-binding epidermal growth factor, and the
ECM components gelatin, type IV collagen, and fi-
bronectin (43–46), and may therefore be significant in
painful tendinopathy, both as a regulator of cytokine
activity and as a mediator of ECM degradation.
ADAM-12 is also reported to support cell attachment
and influence cell spreading and migration (47–49).
Rounded cells are observed more frequently in patho-
logic tendons (50) and it is possible that ADAM-12 may
influence this morphologic feature of the cells.
The MMP-23 mRNA expression level in the
painful tendon samples was 5-fold higher compared
with that in both the normal and ruptured tendon
groups, and we have therefore identified this proteinase
as an interesting target for further study with regard to
understanding painful tendinopathy. The physiologic
substrates and functions of MMP-23 are unknown, but
gelatinolytic activity has been demonstrated, an activity
that could be inhibited by both synthetic inhibitors and
TIMPs 1 and 2 (51,52). The level of MMP-23 mRNA
was observed to peak during an experimentally induced
endochondral bone formation, with both osteoblasts and
chondrocytes expressing the gene (53). Since fibrocarti-
lagenous transformation and endochondral ossification
Table 2. Summary of genes possessing an altered expression level in tendon samples from individuals
with chronically painful tendinopathy or in individuals with ruptured tendon, as compared with normal
Achilles tendon samples*
Painful tendinopathy Ruptured tendon
Higher gene expression under
pathologic conditions
MMP -11, -16, -23 -1, -9, -11, -14, -17, -19, -25
ADAMTS -2, -3 -4
ADAM -12 -8, -12
TIMP – -1
Lower gene expression under
pathologic conditions
MMP -3, -10, -12, -27 -3, -7, -24, -28
ADAMTS -5 -7, -13
ADAM – –
TIMP -3 -2, -3, -4
* See Table 1 for definitions.
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are frequently associated with tendinopathies (54),
MMP-23 may have a role in the altered phenotype of the
tendon cells.
Compared with the normal tendon group, the
levels of TIMP-3 mRNA were lower in the painful
tendon group. TIMP-3 is believed to be the primary
endogenous inhibitor of the aggrecanase ADAMTS
proteinases (23,55) and the ADAM-12 and -17 protein-
ases (21,22,43), and a decrease in TIMP-3 might there-
fore be predicted to influence the activity of these
proteinases. TIMP-3 has also been demonstrated to
possess an antiangiogenic activity (56,57), and a lower
TIMP-3 expression in pathologic tissue may correlate
with the increased incidence of vascular invasion that
has been reported in chronic pathologic conditions in
the tendon (1,58).
Although not addressed directly in this study, an
altered proteolytic profile may contribute to the chronic
pain phenotype. Enzyme activity and proteolytic remod-
eling of the highly ordered matrix would compromise the
mechanical properties of the tissue, potentially increas-
ing the stretch activation of mechanoreceptors, as well as
affecting various cell activities. In conjunction with re-
ductions in antiangiogenic factors (such as TIMP-3),
proteolytic activities are also likely to play an important
role in the infiltration of vessels and nerves commonly
seen in painful Achilles tendinopathy (1,2,29). A mech-
anism such as this is consistent with the hypothesis that
increased innervation and the local release of neuro-
transmitters, such as glutamate, substance P, and calci-
tonin gene-related peptide, are implicated in the percep-
tion of pain and the chronicity of the disease process
(29,59,60).
The significant changes in ruptured tendons,
compared with normal tissue, are summarized in Table
2. Four of these changes, increased levels of ADAM-12
and MMP-11 and lower levels of TIMP-3 and MMP-3,
were also identified in comparisons of the painful and
normal samples. Other differences compared with nor-
mal tendon included an increased expression of
ADAM-8, ADAMTS-4 (aggrecanase 1), MMP-1 (colla-
genase 1), several membrane-type metalloproteinases
(MMPs 14, 17, and 25), MMP-9 (gelatinase B), MMP-
19, and TIMP-1. There were also lower mRNA levels of
ADAMTS-7, ADAMTS-13 (von Willebrand factor
cleaving proteinase), MMPs 7, 24, and 28, and TIMPs 2
and 4. The pathologic significance of these findings
needs to be addressed in followup studies, since some or
all of these changes might have occurred following
rupture in the period prior to surgery. However, all
samples were obtained as soon as possible after rupture,
several within 24 hours, and there was no apparent effect
of the time period preceding surgery.
The greatest of the observed differences was the
1,000-fold higher level of MMP-1 mRNA in the rup-
tured tendons, which suggests that there is a high level of
collagen degradation occurring in tendons that have
ruptured. This would substantially reduce the material
properties of the tendon, supporting the case for early
repair, if the surgical option is to be considered. These
data are consistent with previous observations made by
us, demonstrating an increase in MMP-1 activity and
decrease in MMP-3 activity in torn rotator cuffs (7).
Taken together, these data suggest that MMP-1 is the
predominant collagenase associated with Achilles ten-
don rupture. As observed with the painful samples,
ruptured tendon samples possessed lower levels of
MMP-3 mRNA compared with the normal tendon sam-
ples, which is consistent with previous results (7). How-
ever, unlike the painful tendons, in which the level of
MMP-10 mRNA was also lower, the MMP-10 mRNA
levels in the ruptured samples did not differ from those
in the normal tendons, an observation consistent with
recent findings in the torn rotator cuff (61).
We also have shown that ruptured tendons have
lower levels of TIMPs 2, 3, and 4 mRNA compared with
normal tendons, and similar data were reported in the
rotator cuff (61). Unlike the results in the rotator cuff
study, however, an increase in the level of TIMP-1
mRNA was observed in the ruptured Achilles tendon
samples. Although an overall reduction in TIMP protein
levels would provide an environment more permissible
to metalloproteinase activity, a shift in TIMP balance
toward TIMP-1 may also be of significance, since
TIMP-1 differs in its activity compared with that of the
other TIMP members (62). Unlike other TIMP mem-
bers, TIMP-1 shows little inhibitory activity toward
MMP-19 or the membrane-type MMPs, MMPs 14, 15,
16, and 24 (20).
The level of MMP-19 mRNA was greater in
ruptured samples compared with normal samples. This,
together with the observed shift in balance of TIMP
mRNA levels toward TIMP-1 in ruptured samples,
might therefore result in a greater activity of this met-
alloproteinase in these samples. MMP-19, originally
isolated as an autoantigen from the synovium of a
rheumatoid arthritis patient (63), is widely expressed in
human tissues under quiescent conditions and is proteo-
lytically active against many components of basement
membranes, but is unable to cleave triple helix collagen
(64,65). Its substrates include nidogen 1, and this cleav-
age is thought to be inhibitory to angiogenesis (66).
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Expression of MMP-19 is up-regulated following dermal
wounding (66), and its higher expression in ruptured
tendon samples may therefore be indicative of a wound
repair response.
As many differences were observed between the
chronically painful and ruptured tendons as were ob-
served between either of the pathologic tendon groups
and the normal tissue group. These differences include a
higher level of mRNA for ADAMs 8 and 12,
ADAMTS-4, MMPs 1, 8, 10, 12, 19, and 25, and TIMP-1
and lower level of mRNA for ADAMTS-2, -3, -10, and
-17, MMPs 7, 16, 21, 23, 24, and 28, and TIMPs 2, 3, and
4 in ruptured tendons compared with painful tendons.
The mRNA expression data therefore suggest that these
2 sample groups represent distinct tissue states. This
viewpoint was supported by the histologic examination
of the samples, which identified a number of differences
between these groups, particularly a greater cellularity,
vascularization, and glycosaminoglycan content in the
painful tendon group.
The apparent differences between these groups
may reflect the initial criteria for inclusion of samples
into each group, which define distinct clinical pathologic
characteristics; that is, painful tendon samples were
from patients who had experienced more than 6 months
of pain in the tendon prior to surgery, whereas ruptured
tendon samples were from patients who had experienced
a tendon rupture without a known clinical history of pain
in the tendon. The chronic nature of the condition in the
painful tendon group suggests that differences in the
histologic features and mRNA expression levels com-
pared with those in normal tendon represent the patho-
logic state. In contrast, differences in histologic features
and mRNA expression in the ruptured tendon group
may have occurred pre- or postrupture and are likely to
represent early reparative responses in addition to pos-
sible underlying pathologic changes. Although the de-
sign of the present study did not allow us to address the
pathologic progression in the tendon, it may be specu-
lated that tendon pain and rupture are distinct pheno-
types and that pain is not necessarily part of a progres-
sion to rupture.
In summary, this study is the first comprehensive
screen of metalloproteinase and TIMP mRNA expres-
sion in Achilles tendon, and provides a comparison
between normal tendon, tendon following rupture, and
tendon in patients experiencing chronic pain. This study
has revealed characteristic mRNA profiles of these 3
tendon states and was able to identify a number of genes
worthy of further study. It is hoped that these data will
form a basis from which the roles of metalloproteinases
and their inhibitors in pathologic conditions of the
tendon can be understood.
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